Skip to main content
padlock icon - secure page this page is secure

Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy

Buy Article:

$68.00 + tax (Refund Policy)

Animal models of human cancer have evolved in attempts to capture the complexity of the human disease. They encompass two broad types of model, namely those in which the tumor arises in situ and those in which cancer cells or tissue are transplanted. Currently human tumor xenografts are the most widely used model to help predict antitumor efficacy in a preclinical setting and xenograft results for certain disease types such as ovarian cancer and non-small cell lung cancer correlate well with clinical activity if the models are used under appropriate conditions. The genetically engineered mouse (GEM) models allow study of the effects of targeted inhibitors against defined molecular targets. These are becoming increasingly sophisticated to recapitulate the progression of tissue-specific molecular changes found within individual cancers. Non-germline GEM models possess the ability to study the impact of specific cancer genes without some of the limitations inherent in traditional GEM models. While rodents, particularly mice, have been the animal host most frequently used, there is increasing recognition of the value of using larger species especially dogs in the veterinary oncology setting. These have successfully modelled aspects of selected human cancers such as osteosarcoma, GIST and prostate cancer. Individually, these models have relative strengths and weaknesses in mimicking the human disease and appropriately reflecting its cellular and molecular pathology. This review will seek to address where these models can be best used to help predict response to therapeutics.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Canine; Non-germline GEM; genetically engineered mice; genotypic and phenotypic characteristics; model; murine; preclinical; rodent cancer cells; tissues; transplantable; xenograft

Document Type: Research Article

Publication date: November 1, 2012

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more